Select Page

KOL Meeting Preparation Using Claude.ai 3.7

Prompt provided by Patrina Pellet, PhDYou are a seasoned senior MSL with deep expertise in identifying what different Key Opinion Leaders (KOLs) value most in order to build long-term, trust-based relationships. I need your strategic insight to help me prepare for an upcoming meeting with a KOL. Here’s what I know so far:
• KOL Name: Ola Landgren
• Institution: University of Miami
• Area of Expertise: Myeloma
• Relevant Publication(s):
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2.
N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.
J Clin Oncol. 2024 Apr 10;42(11):1229-1240. doi: 10.1200/JCO.23.01277. Epub 2024 Jan 9.
Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31. Based on this, please provide thoughtful, high-level guidance on the following:

1. Motivations & Drivers
What are this KOL’s likely core motivations? For example, if they are heavily involved in clinical research, what specific interests or goals might they have (e.g., innovation, trial design, translational science, patient outcomes)?
2. Pain Points & Challenges
What are the likely challenges or unmet needs they face within their area of expertise?
3. Emerging Topics & Trends
What trends, disruptive technologies, or emerging research areas are most likely to capture their attention based on their current work?
4. Value-Add Opportunities
What types of data, resources, insights, or support could I offer to meaningfully support their goals and build credibility?
5. Personalized Engagement
How can I tailor my communication and engagement style to align with their professional values and preferences?
6. Conversation Starters
What topics or insights from their recent publications or public presentations would serve as strong conversation openers?
7. Strategic Relationships
Who might be their key collaborators, influencers, or professional network nodes—and how might I reference or leverage those connections?
8. Communication Style Alignment
Based on their presentation, writing, or interview style, how should I adapt my tone, language, or pacing?
9. Post-Meeting Follow-Up
What follow-up actions or touchpoints could I take to remain visible and valuable after the meeting?
10. Personal Touchpoints
Are there any known non-professional interests, causes, or affiliations I could authentically reference to help build rapport?

Results from Claude.ai 3.7

1. Motivations & Drivers

Dr. Landgren appears primarily motivated by advancing precision medicine approaches in multiple myeloma. His publication history suggests strong interests in minimal residual disease (MRD) detection, early intervention strategies, and developing novel therapeutic approaches that improve patient outcomes. He likely values innovation in diagnostics and treatment paradigms that can transform standard of care.

2. Pain Points & Challenges

Key challenges in Dr. Landgren’s field likely include:

  • Limited sensitivity of current MRD detection methods
  • Translating research findings into clinical practice
  • Drug resistance in relapsed/refractory patients
  • Identifying biomarkers that can predict treatment response
  • Optimizing treatment sequencing with the growing number of available therapies
  • Funding for innovative research approaches

3. Emerging Topics & Trends
Based on his recent publications, Dr. Landgren is likely interested in:

  • Immunotherapy advances including CAR-T and bispecific antibodies
  • Novel MRD assessment technologies (next-generation sequencing, mass spectrometry)
  • Liquid biopsy approaches
  • Big data/AI applications in predicting disease progression
  • Personalized medicine approaches based on genomic profiling
  • Early intervention strategies for smoldering myeloma

4. Value-Add Opportunities
Consider offering:

  • Access to emerging clinical trial data relevant to his research interests
  • Connections to other researchers in complementary fields
  • Information on novel technologies for MRD assessment
  • Resources to support patient education initiatives
  • Opportunities for investigator-initiated studies
  • Support for data analysis or biostatistical expertise

5. Personalized Engagement
Engage Dr. Landgren with a scientifically rigorous approach that demonstrates you’ve thoroughly researched his work. Come prepared with specific questions about his research methodology and findings. Focus on how your organization can support his scientific goals rather than product-focused discussions.
6. Conversation Starters
Some potential conversation openers based on his recent publications:

  • “I was intrigued by your 2023 Nature Medicine publication exploring novel biomarkers. What do you see as the next frontier in this area?”
  • “Your recent JCO paper on treatment sequencing raises interesting questions about optimizing therapy. How do you see the treatment landscape evolving?”
  • “Your work on MRD detection has been groundbreaking. What technological advances do you find most promising for increasing sensitivity?”

7. Strategic Relationships
Dr. Landgren likely collaborates with:

  • Other myeloma specialists at major academic centers
  • Laboratory scientists focused on genomics and proteomics
  • Biostatisticians and data scientists
  • Clinical trial network leaders
  • Patient advocacy organizations
  • Industry partners developing novel therapeutics or diagnostics

Consider referencing relevant collaborations in a way that demonstrates your understanding of the research ecosystem.
8. Communication Style Alignment
Based on his academic publications, Dr. Landgren likely values:

  • Data-driven discussions with specific evidence
  • Logical, well-structured arguments
  • Precise scientific language
  • Recognition of limitations and nuance
  • Direct, efficient communication

Adjust your style to be scientifically precise, evidence-based, and focused on meaningful outcomes rather than promotional.
9. Post-Meeting Follow-Up
Effective follow-up strategies include:

  • Sharing relevant scientific publications that connect to your discussion
  • Providing requested information or resources promptly
  • Connecting him with relevant experts within your organization
  • Following up on any specific questions that required additional research
  • Proposing a concrete next step or follow-up meeting with clear objectives

10. Personal Touchpoints
Without specific information about Dr. Landgren’s personal interests, I recommend:

  • Acknowledging his contributions to the field respectfully
  • Recognizing the impact of his work on patient care
  • Expressing genuine interest in his research journey and what led him to focus on myeloma
  • Asking about his mentorship experiences or educational initiatives
  • Inquiring about his experiences at University of Miami and how the institutional environment supports his research goals